NeurologyOnline.net

Neurology Xagena

Xagena Mappa
Medical Meeting
Gastrobase.it
Xagena Salute

Search results for "Tysabri"

The Food and Drug Administration ( FDA ) issued a public health advisory to inform patients and health care providers about the suspended marketing of Tysabri ( Nataluzimab ) while the agency and the ...


Two-year data from the AFFIRM Phase III monotherapy trial, presented at 57th annual American Academy of Neurology ( AAN ) meeting, showed that treatment with Natalizumab ( Tysabri ) led to a significa ...


One-year data from the Phase III SENTINEL trial, presented at the 57th Annual Meeting - American Academy of Neurology ( AAN ), demonstrated that when Natalizumab ( Tysabri ) was added to Interferon be ...


The virus responsible for PML ( progressive multifocal leukoencephalopathy ), a rare brain disease that typically affects AIDS patients and other individuals with compromised immune systems, has bee ...


At the end of July 2008, two cases of progressive multifocal leukoencephalopathy ( PML ) were reported in patients with multiple sclerosis receiving Natalizumab ( Tysabri ) in the European post-mark ...


Biogen Idec and Elan Corporation have announced that they have submitted applications to the FDA ( Food and Drug Administration ) and EMA ( European Medicines Agency ) requesting updates to the Tysabr ...


Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more than two months. ...


The evaluation of therapeutic choices is needed after 24 doses of Natalizumab ( Tysabri ) in patients with multiple sclerosis ( MS ). A study has evaluated the effect of therapeutic choices on the me ...


Phase IIa clinical trial data on ATL1102 were published in the medical journal Neurology. The article highlights the successful outcomes of the randomised, double-blind, placebo-controlled study in 77 ...


The lack of prospective trial data comparing certain multiple sclerosis therapies could be addressed with observational research. Researchers have investigated outcomes of Natalizumab ( Tysabri ) v ...


Natalizumab ( Tysabri ) has shown its efficacy in reducing multiple sclerosis ( MS ) relapses and progression of disability; however, it has been associated with an increased risk of developing progre ...


Previous therapeutic strategies for multiple sclerosis ( MS ) include the non-selective suppression of systemic immunity ( immunosuppressive agents, such as glucocorticoids, Mitoxantrone and Azathiopr ...


The phase 3 ASCEND study investigating Natalizumab ( Tysabri ) in the treatment of secondary progressive multiple sclerosis ( SPMS ) did not achieve its primary and secondary endpoints. During the stu ...


Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more than 2 million people worldwide. The disease usually starts in early adulthood, but the ...